{
    "clinical_study": {
        "@rank": "68835", 
        "arm_group": {
            "arm_group_label": "dabrafenib + trametinib", 
            "arm_group_type": "Experimental", 
            "description": "Combination therapy of dabrafenib and trametinib"
        }, 
        "brief_summary": {
            "textblock": "This is a Japanese Phase I/II, open-label, non-controlled study to evaluate the safety,\n      tolerability, pharmacokinetic profile, and efficacy of the combination of GSK2118436 and\n      GSK1120212 in subjects with BRAF V600E/K mutation positive advanced solid tumors (Phase I\n      part) and BRAF V600E/K mutation positive cutaneous melanoma (Phase II part)."
        }, 
        "brief_title": "Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumours", 
        "condition_browse": {
            "mesh_term": [
                "Melanoma", 
                "Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Japanese Phase I/II, open-label, non-controlled study to evaluate the safety,\n      tolerability, pharmacokinetic profile, and efficacy of the combination of GSK2118436 and\n      GSK1120212 in subjects with BRAF V600E/K mutation positive advanced solid tumors (Phase I\n      part) and BRAF V600E/K mutation positive cutaneous melanoma (Phase II part). Phase I part is\n      designed to primarily assess the safety and tolerability of GSK2118436 and GSK1120212\n      combination therapy in subjects with BRAF V600E/K mutation positive advanced solid tumors.\n      Six evaluable subjects will be enrolled into Phase I part and receive the combination\n      therapy of GSK2118436 (150 mg, twice daily) and GSK1120212 (2 mg, once daily). A decision\n      for starting Phase II part will be made by careful review based on available safety,\n      tolerability and pharmacokinetic data in Phase I part. Phase II part is designed to\n      primarily evaluate ORR of the combination as first-line therapy in subjects with\n      unresectable (Stage IIIC) or metastatic (Stage IV) BRAF V600E/K mutation positive cutaneous\n      melanoma. Subjects who have had prior systemic anti-cancer treatment in the advanced or\n      metastatic setting will not be eligible for Phase II part although prior systemic treatment\n      in the adjuvant setting will be allowed. Six evaluable subjects will be enrolled in Phase II\n      part."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Capable of given written informed consent, which includes compliance with the\n             requirements and restrictions listed in the consent form.\n\n          -  Male or female age 20 years or greater; able to swallow and retain oral medication.\n\n          -  BRAF mutation positive advanced solid tumor ( Phase I part). BRAF mutation positive\n             melanoma (Phase II part).\n\n          -  Measurable disease according to RECIST version 1.1.\n\n          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1\n\n          -  Agree to contraception requirements.\n\n          -  Adequate organ system function.\n\n        Exclusion Criteria:\n\n          -  Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy,\n             or biologic therapy).\n\n          -  Phase II part ONLY: Prior systemic anti-cancer treatment (chemotherapy,\n             immunotherapy, biologic therapy, vaccine therapy, or investigational treatment) for\n             Stage IIIC (unresectable) or Stage IV (metastatic) melanoma. Prior systemic treatment\n             in the adjuvant setting is allowed.\n\n          -  Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity,\n             biologic therapy, or immunotherapy within 28 days prior to the study treatment (6\n             weeks for prior nitrosourea or mitomycin C), or daily or weekly chemotherapy without\n             the potential for delayed toxicity within 14 days prior to the study treatment.\n             Limited radiotherapy within the last 2 weeks. (Note: Ipilimumab treatment must end at\n             least 8 weeks prior to the study treatment.)\n\n          -  Taken an investigational drug within 28 days or 5 half-lives (minimum 14 days),\n             whichever is shorter, prior to the study treatment.\n\n          -  Current use of a prohibited medication or requires any of these medications during\n             treatment with the study drugs.\n\n          -  A history of another malignancy. Subjects who have been disease-free for 5 years, or\n             subjects with a history of completely resected non-melanoma skin cancer, or\n             successfully treated in situ carcinoma are eligible.\n\n          -  Any serious or unstable pre-existing medical conditions (aside from malignancy\n             exceptions specified above), psychiatric disorders, or other conditions that could\n             interfere with the subject's safety, obtaining informed consent, or compliance with\n             study procedures (e.g., uncontrolled diabetes).\n\n          -  Presence of active gastrointestinal disease or other condition that will interfere\n             significantly with the absorption, distribution, metabolism, or excretion of drugs.\n\n          -  History of pneumonitis or interstitial lung disease.\n\n          -  Known HIV infection.\n\n          -  Certain cardiac abnormality\n\n          -  A history or current evidence/risk of retinal vein occlusion or central serous\n             retinopathy.\n\n          -  Pregnant or lactating female."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01928940", 
            "org_study_id": "116885"
        }, 
        "intervention": [
            {
                "arm_group_label": "dabrafenib + trametinib", 
                "description": "150 mg twice daily", 
                "intervention_name": "dabrafenib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "dabrafenib + trametinib", 
                "description": "2 mg once daily", 
                "intervention_name": "trametinib", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Advanced solid tumors", 
            "BRAF", 
            "Melanoma"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Shizuoka", 
                        "country": "Japan", 
                        "zip": "411-8777"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "104-0045"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Japanese Open-label Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of GSK2118436 and GSK1120212 Combination Therapy in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) and BRAF V600E/K Mutation Positive Cutaneous Melanoma (Phase II Part).", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Adverse Events will be graded by the investigators according to the NCI-CTCAE v4.0.", 
                "measure": "Number of participants with adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "According to Response Evaluation Criteria in Solid tumors (RECIST) v 1.1.", 
                "measure": "Response rate (complete response + partial response).", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01928940"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "According to Response Evaluation Criteria in Solid tumors (RECIST) v 1.1.", 
                "measure": "Response duration.", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "According to Response Evaluation Criteria in Solid tumors (RECIST) v 1.1.", 
                "measure": "Progression-free survival.", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Area under the plasma concentration versus time curve (AUC) of GSK2118436 and its metabolite(s), and GSK1120212", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Peak Plasma Concentration (Cmax) of GSK2118436 and its metabolite(s), and GSK1120212", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Levels of circulating cytokines", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Gene mutation in tumor tissues", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}